Noticias y Actividades de Serb Pharmaceuticals

Serb Pharmaceuticals tiene presencia directa en 2 países.

Ellos se encuentran en:

• Farmacia50%
• Biotecnología50%

Fusión, adquisición y financiación con participación de Serb Pharmaceuticals.

• Serb Pharmaceuticals ha Y-mAbs Therapeutics adquirido (publicado el 17 de septiembre de 2025).
• Serb Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics  (publicado el 6 de agosto de 2025).

Ver el organigrama con sus 35 ejecutivos principales

Biografías más buscadas en Serb Pharmaceuticals

• Vanessa Wolfeler, Chief Executive Officer
• Jeremie Urbain, Chairman of the Board
• Arthur Pignot, Chief Strategy Officer

Recientes movimientos de ejecutivos en Serb Pharmaceuticals

• Cecile Baradez, se ha incorporado a la empresa como Medical Science Liaisons Director  (noticia publicada el 11 de mayo de 2026).
• Neha Chawla que ha sido Senior Director, Commercial Operations, ha ascendido a Executive Director, Commercial Operations  (noticia publicada el 24 de marzo de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en Serb Pharmaceuticals.

Serb Pharmaceuticals tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).

Popular M&A news in Farmacia

• Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
• Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
• Apotex ha presentado su expediente de OPI. Su símbolo de cotización será TSX. (publicado el 2 de junio de 2026).

Otros contactos sugeridos en el sector Farmacia

• Joaquin Duato - Chief Executive Officer and Chairman of the Board en Johnson & Johnson
• Richard Saynor - Chief Executive Officer en Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board en Abbott

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Serb Pharmaceuticals

• SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million - SERB Pharmaceuticals
• SERB Pharmaceuticals Announces ThyroSafe 130mg Potassium Iodide Tablets are Now Commercially Available in the US - SERB Pharmaceuticals
• Y-mAbs Announces Publication in Cancers - SERB Pharmaceuticals
• SERB Pharmaceuticals Expands Scientific Leadership with Appointment of Dr. Peter C. Adamson to US Board  - SERB Pharmaceuticals
• Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical Officer - SERB Pharmaceuticals
• SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics - SERB Pharmaceuticals
• SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - SERB Pharmaceuticals
• SFJ Pharmaceuticals and SERB Pharmaceuticals Present Positive Final Results from Pivotal Phase 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding  - SERB Ph
• Newly published study shows that Voraxaze® can improve clinical outcomes in patients with high-dose methotrexate induced acute kidney injury - SERB Pharmaceuticals
• First FDA-approved treatment for severe frostbite now commercially available in the US  - SERB Pharmaceuticals
• View more press releases Close

Redes sociales sobre Serb Pharmaceuticals

• Serb Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Serb Pharmaceuticals en LinkedIn, Twitter y YouTube